RESTASIS Drug Patent Profile

Which patents cover Restasis, and what generic alternatives are available?

Restasis is a drug marketed by Abbvie and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in RESTASIS is cyclosporine. There are eighteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Restasis

A generic version of RESTASIS was approved as cyclosporine by HIKMA on October 29^th, 1999.

Summary for RESTASIS

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RESTASIS

US Patents and Regulatory Information for RESTASIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RESTASIS	cyclosporine	EMULSION;OPHTHALMIC	050790-001	Dec 23, 2002	AB	RX	Yes	Yes
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes			Y		Y
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes			Y		Y
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes			Y		Y

International Patents for RESTASIS

See the table below for patents covering RESTASIS around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	287635	PHARMACEUTICAL EMULSION COMPOSITION COMPRISING A CYCLOSPORIN, FATTY ACID AND PEMULEN STABILISER, USE IN TOPICAL APPLICATION TO OCCULAR TISSUE
Japan	H0667850
Australia	2014368816	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
South Korea	100450703

Supplementary Protection Certificates for RESTASIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	LUC00006	Luxembourg		PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323

Investment Scenario and Fundamentals Analysis for RESTASIS

Last updated: February 20, 2026

What Is RESTASIS?

RESTASIS (cyclosporine ophthalmic emulsion 0.05%) is an eye drop indicated for increasing tear production in patients with chronic dry eye caused by inflammation. It was approved by the FDA in 2002 and marketed by AbbVie Inc. (previously Allergan). The drug is delivered via a proprietary formulation designed to enhance bioavailability and reduce systemic absorption.

Market Overview and Revenue Dynamics

RESTASIS remains a leading treatment for dry eye disease (DED), especially for patients unresponsive to artificial tears. In 2022, global sales approached $1.1 billion, representing a decline from peak sales of $1.4 billion in 2014 due to patent expiry and generic competition.

Revenue Breakdown (2022)

Source	Share	Revenue (USD millions)
Branded RESTASIS	65%	715
Generics (Authorized/Competitors)	35%	385

Key Factors Affecting Revenue

• Patent expiry in 2018 for the original formulation.
• Introduction of generic versions from Teva Pharmaceuticals, Sandoz, and others post-2018.
• Market saturation with existing formulations; limited pipeline for new indications.
• Growing use of alternative therapies such as lifitegrast (Xiidra) and cyclosporine formulations with different delivery systems.

Fundamentals and Key Investment Considerations

Patent and Regulatory Environment

• Original patents for RESTASIS expired in 2018, opening the market for generics.
• AbbVie launched a Strengthened Formulation (Restasis Multi-dose or "Restasis Multi-dose preservative-free") in 2021 to extend product life, though patent challenges persist.
• Litigation over patent infringements has delayed generic entry until 2024-2025.

Competitive Landscape

• Generics have eroded sales; branded revenues decreased 17% annually from 2018 to 2022.
• The introduction of alternative therapies, including Xiidra (lifitegrast), which achieved approximately $350 million in 2022, challenges RESTASIS's market dominance.
• Ophthalmic drug market shows slow growth, estimated CAGR of 1.8% over 2022-2027.

Financial Metrics

Metric	2022 Data
Revenue	USD 715 million
Operating Margin	~25%
R&D Expenditure	USD 45 million (approx. 6.3% of revenue)
Patent Portfolio Status	Ongoing litigation until 2024-2025

R&D and Pipeline

• ABBVIE’s focus on developing new dry eye therapies remains limited; current pipeline includes early-stage compounds.
• No significant expansion of indications or reformulations targeted at alternative dry eye subpopulations.

Investment Risks

• Patent expiry and patent challenges threaten continued revenue.
• Competition from generics and alternative treatments may limit commercial upside.
• Market saturation constrains growth potential, with flat to declining revenue prospects in the near term.

Valuation

• As of 2023, RESTASIS's valuation hinges mainly on its branded revenue stability and potential pipeline success.
• The company's overall ophthalmology segment, including RESTASIS, has a valuation multiple around 12-14x trailing EBITDA, with declining revenues influencing multiples.

Strategic Outlook

• Revenue stabilization hinges on patent litigation outcomes and potential expansion of new formulations or indications.
• Market share gains from new formulations have been limited.
• The pipeline appears inactive for new indications specific to dry eye disease.

Summary

RESTASIS's investment outlook faces headwinds from patent expirations, generic competition, and market saturation. Its current revenue relies on a mature product facing decline. Near-term growth prospects remain limited unless AbbVie can leverage litigation outcomes or develop innovative therapies.

---

Key Takeaways

• Revenue declined from peak levels due to patent expiry and generic competition; 2022 sales stood at USD 715 million.
• Patent litigation prolongs the exclusivity period until 2024-2025, influencing revenue prospects.
• Competition from generics and alternative dry eye drugs limits market share and growth.
• The pipeline shows limited activity outside existing formulations; no significant pipeline catalysts are evident.
• Valuations are pressured by revenue trajectory and patent challenges, with downside risk if generics accelerate market penetration.

---

FAQs

1. How long do patent protections for RESTASIS last?
Patent protections for the original formulation expired in 2018, but AbbVie has litigated to extend patent rights through new formulations and patent lawsuits. Patent protection is expected to last until 2024-2025.

2. What are the main competitive threats to RESTASIS?
Generic versions of cyclosporine, alternative therapies like Xiidra (lifitegrast), and new delivery systems present competitive challenges.

3. Can pipeline developments turn around RESTASIS revenues?
Current pipeline activity shows limited prospects; no new indications or formulations are in advanced stages, reducing potential upside.

4. How significant is the impact of generics on sales?
Generic competition caused a 17% revenue decline annually from 2018 to 2022, heavily impacting branded sales.

5. What is the outlook for dry eye market growth?
The market grows at a CAGR of approximately 1.8%, with slow adoption of new therapies and increasing competition constraining revenue expansion.

---

References

[1] Deloitte. (2023). Ophthalmic drugs market analysis.
[2] FDA. (2022). Drug approvals data.
[3] EvaluatePharma. (2023). Market forecast report.
[4] Abbott. (2023). Financial statements.
[5] IQVIA. (2022). Pharmaceuticals market data.